BridgeBio Pharma, Inc. — Director's Dealing 2023

Dec 19, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-12-15

Reporting Person: Valantine Hannah (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-15	Common Stock	M	2915	$8.45	Acquired	4679	Direct
2023-12-15	Common Stock	S	2915	$36.12	Disposed	1764	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-15	Stock Option (right to buy)	$8.45	M	2915	Disposed	2032-06-22	Common Stock (2915)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023.

F2: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.